12-12-2021, 04:04 PM
Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
Graph A shows the level of antibodies over time (30, 60, ... days)
B, C, and D show different kinds antibodies at the same time (shortly after infection or vaccination)
A thru D are measures of how effective the antibodies were against one particular culture of COVID.
E and F are the same graph as D but against two other cultures of COVID.
In each graph are different groups of people. Â Purple triangles are vaccinated people that got Delta (so probably recently).
The cyan diamonds are people who were infected with COVID (original or other) and then got vaccinated.
The orange circles are people who have been vaccinated but not had COVID.
The gray squares are people that were infected (in WA in 2020) but not vaccinated.
The white circles are people that were not vaccinated and not had COVID.
2X means two vaccinations. Â 3X means three vaccinations
![[Image: COVIDab-Walls.png]](https://i.ibb.co/0KS9QYT/COVIDab-Walls.png)
Quote:However, we show that Delta breakthrough cases,  subjects who were vaccinated after Â
SARS-CoV-2 infection and individuals vaccinated three times (without infection) have Â
serum neutralizing activity of comparable magnitude and breadth indicate that multiple Â
types of exposure or increased number of exposures to SARS-CoV-2 antigen(s) enhanceÂ
spike-specific antibody responses.
Graph A shows the level of antibodies over time (30, 60, ... days)
B, C, and D show different kinds antibodies at the same time (shortly after infection or vaccination)
A thru D are measures of how effective the antibodies were against one particular culture of COVID.
E and F are the same graph as D but against two other cultures of COVID.
In each graph are different groups of people. Â Purple triangles are vaccinated people that got Delta (so probably recently).
The cyan diamonds are people who were infected with COVID (original or other) and then got vaccinated.
The orange circles are people who have been vaccinated but not had COVID.
The gray squares are people that were infected (in WA in 2020) but not vaccinated.
The white circles are people that were not vaccinated and not had COVID.
2X means two vaccinations. Â 3X means three vaccinations
Quote:Figure 1: Repeated exposures to SARS-CoV-2 antigens through vaccination or infection enhance S-specific serum IgG and IgA binding titers.Â
(A) Serum IgG binding titers at 30 or 60 days post infection or 10, 112, or 180 days post second or third vaccine dose were evaluated
for longitudinal samples by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as
antigen. Serum samples were obtained from individuals who had a Delta breakthrough infection
(n=15, magenta triangle), were previously infected then vaccinated (n=15, teal diamond), have
only been vaccinated (n=15, orange circle), were infected in 2020 in Washington State (n=15,
gray square), or were SARS-CoV-2 naive (samples taken prior to vaccination, n=15, open
hexagon). Â
(B) Serum IgA binding titers at 30 days post infection or 10 days post second
vaccine dose were evaluated by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as
antigen.Â
© Serum IgM binding titers at 30 days post infection or 10 days post second vaccine
dose were evaluated by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as antigen.Â
(D) Serum IgG binding titers were evaluated by ELISA at 30 days post infection, 10 days postÂ
second or third   vaccine dose or prior to SARS-CoV-2 exposure (SARS-CoV-2 naive) using Â
prefusion-stabilized SARS-CoV 2P S as antigen.Â
(E-F) Serum IgG binding titers were evaluatedÂ
at 30 days post infection, 10 days post second or third vaccine dose, or prior to SARS-CoV-2Â
exposure (SARS-CoV-2 naive) by ELISA using OC43 S (E) or HKU1 2P S (F) as antigen. # ofÂ
doses: number of vaccine doses received.Â